Bluebird’s new data for LentiGlobin for TDT

Bluebird (NASDAQ:BLUE) comments on long-term safety and efficacy data for LentiGlobin gene therapy for Transfusion-dependent β-Thalassemia.

In the Phase 1/2 Northstar study, patients with TDT who don’t have a β0/β0 genotype achieved up to 3.8 years of transfusion independence.

In the ongoing Phase 3 Northstar-2 study, four of five evaluable study patients (with TDT, without β0/β0 genotype) achieved transfusion independence.

https://seekingalpha.com/news/3471350-bluebirds-new-data-lentiglobin-tdt